A recent trial among patients with pre‐diabetes using higher doses of liraglutide (3.0 mg) for weight loss also reported a higher proportion of AP diagnoses among the liraglutide group (0.7%; 12 cases) vs those who received placebo (0.3%; two cases).42 Overall, however, there appears to be increasing support for the absence of association between GLP‐1 RA therapies and AP.15 This evidence concerns the gene GCG and diabetes mellitus.